[1] STOLZ M,GOWLAND P,TINGUELY C,et al.Safe-testing algorithm for individual-donation nucleic acid testing:10 years of experience in a low-prevalence country[J].Transfus Med Hemother,2019,46(2):104-110. [2] 尹丹,欧阳熊妍,陈雪,等.重庆地区血液筛查核酸联检与鉴别检测结果不一致标本OBI确认[J].重庆医学,2020,49(20):3376-3380. [3] 周璐. 核酸检测重复无反应性的血液HBV残留风险[D].大连:大连医科大学,2018. [4] 邓雪莲,李婷婷,郭笑寒,等.核酸检测非重复反应性的HBsAg阴性血液HBV感染的确认[J].中国输血杂志,2018,31(9):962-967. [5] BAKKOUR S,DENG X T,BACCHETTI P,et al.Replicate aptima assay for quantifying residual plasma viremia in individuals on antiretroviral therapy[J].J Clin Microbiol,2020,58(12):e01400-e01420. [6] 杨宇婷. 儿童隐匿性乙肝病毒感染风险及检测方法的研究[D].重庆:重庆医科大学,2020. [7] 易永祥. 乙型肝炎病毒的分子流行病学研究进展[J].新发传染病电子杂志,2020,5(1):1-7. [8] 刘忠萍. 全球乙型肝炎病毒基因型和基因亚型分布的Meta分析[D].安徽医科大学,2020. [9] AL-QAHTANI A A,POURKARIM M R,TROVÃO N S,et al.Molecular epidemiology,phylogenetic analysis and genotype distribution of hepatitis B virus in Saudi Arabia:predominance of genotype D1[J].Infect Genet Evol,2020,77:104051. [10] GOU H N,PAN Y,GE H W,et al.Evaluation of an individual-donation nucleic acid amplification testing algorithm for detecting hepatitis B virus infection in Chinese blood donors[J].Transfusion,2015,55(9):2272-2281. [11] HOSHI Y,HASEGAWA T,YAMAGISHI N,et al.Optimal titer of anti-HBs in blood components derived from donors with anti-HBc[J].Transfusion,2019,59(8):2602-2611. [12] RAIMONDO G,LOCARNINI S,POLLICINO T,et al.Update of the statements on biology and clinical impact of occult hepatitis B virus infection[J].J Hepatol,2019,71(2):397-408. [13] 叶贤林,许晓绚,邵文,等.献血者HBsAg阴性NAT可疑结果标本乙肝感染状况的调查分析[J].中国输血杂志,2019,32(8):798-802. [14] KANG J W,SEO J H,YOUN K W,et al.Use of supplemental anti-HBc testing of donors showing non-discriminating reactive results in multiplex nucleic acid testing[J].Vox Sang,2017,112(7):622-627. |